Athira Pharma, Inc. (ATHA)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Athira Pharma, Inc. (ATHA) trades at $6.75 with AI Score 44/100 (Grade C). Athira Pharma, Inc. is a late clinical-stage biopharmaceutical company focused on developing small molecules to treat neurodegenerative diseases. Market cap: $26.62M, Sector: Healthcare.
Price live · AI analysis from May 10, 2026ATHA stock analysis for 2026: Analysts have set a consensus price target of $4.00 for Athira Pharma, Inc., suggesting 40.7% downside from the current price of $6.75. The AI MoonshotScore is 44/100, indicating a neutral outlook. Key factors: analyst coverage, AI-driven quantitative scoring.
ATHA: the 1 perspectives are evenly split.
How is this calculated? →Athira Pharma, Inc. (ATHA) Healthcare & Pipeline Overview
Athira Pharma, Inc. is a clinical-stage biotechnology company developing small molecule therapeutics for neurodegenerative diseases, primarily Alzheimer's and Parkinson's. Their lead candidate, ATH-1017, is undergoing Phase 3 and Phase 2 clinical trials, positioning Athira in the competitive Alzheimer's treatment landscape with a focus on restoring neuronal health.
What Is the Investment Thesis for ATHA?
Athira Pharma operates in the high-risk, high-reward biotechnology sector, primarily focused on Alzheimer's disease. The investment thesis hinges on the successful completion of Phase 3 trials for ATH-1017 (LIFT-AD) with data expected to be released in the near future. Positive results could lead to accelerated regulatory approval and significant market uptake, given the unmet need in Alzheimer's treatment. Key value drivers include the potential for ATH-1017 to demonstrate disease-modifying effects, differentiating it from existing symptomatic treatments. The company's market capitalization of $26.62M reflects the inherent risks associated with clinical-stage biotech companies. Failure to achieve positive clinical trial outcomes or secure regulatory approval represents significant downside risks.
Based on FMP financials and quantitative analysis
ATHA Key Highlights
- ATH-1017 is in Phase 3 clinical trials (LIFT-AD) for Alzheimer's disease, targeting a large and underserved patient population.
- ATH-1017 is a blood brain barrier-penetrating, small molecule HGF/MET positive modulator, potentially offering a novel mechanism of action.
- The company has preclinical programs (ATH-1019 and ATH-1020) targeting peripheral nervous system and neuropsychiatric conditions, diversifying its pipeline.
- Athira Pharma changed its name from M3 Biotechnology in April 2019, signaling a strategic shift and renewed focus.
- The company is headquartered in Bothell, Washington, a region with a strong biotechnology presence.
Who Are ATHA's Competitors?
ATHA is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| LLY Eli Lilly and Company | $1202.56 | -0.94% | $1.13T | 98 |
| BIIB Biogen Inc. | $212.58 | -1.64% | $31.39B | 78 |
| VTVT vTv Therapeutics Inc. | $35.17 | -0.65% | $92.05M | 39 |
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
| GLUE Monte Rosa Therapeutics, Inc. | $23.06 | -4.75% | $1.50B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ATHA's Key Strengths?
- Novel approach to treating neurodegenerative diseases by restoring neuronal health.
- Lead product candidate, ATH-1017, in Phase 3 clinical trials.
- Experienced management team with expertise in drug development.
- Proprietary small molecule platform.
What Are ATHA's Weaknesses?
- Limited financial resources.
- High dependence on the success of ATH-1017.
- Small number of employees (26).
- High beta of 2.80, indicating high volatility.
What Could Drive ATHA Stock Higher?
- Data readout from the LIFT-AD Phase 3 clinical trial for ATH-1017 in Alzheimer's disease.
- Enrollment and progress in the ACT-AD Phase 2 clinical trial for ATH-1017 in Alzheimer's disease.
- Advancement of preclinical programs for ATH-1019 and ATH-1020.
What Are the Key Risks for ATHA?
- Financial-distress signal — its Altman Z-Score of -9.26 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Failure to achieve positive results in clinical trials.
- Regulatory delays or rejection of ATH-1017.
- Competition from other companies developing Alzheimer's treatments.
- Dependence on securing additional funding to support operations.
- Patent challenges to Athira's intellectual property.
What Are the Growth Opportunities for ATHA?
- Successful Completion of LIFT-AD Phase 3 Trial: The primary growth opportunity lies in the successful completion of the LIFT-AD Phase 3 clinical trial for ATH-1017 in Alzheimer's disease. Positive results, demonstrating statistically significant improvements in cognition and function, could lead to accelerated regulatory approval. The Alzheimer's disease market is estimated to reach $11.57 billion by 2029, presenting a substantial commercial opportunity for Athira if ATH-1017 proves effective. Timeline: Data readout expected in the near future.
- Advancement of Parkinson's Disease Program: Athira is also conducting Phase 2 clinical trials of ATH-1017 in Parkinson's disease. Positive data in this indication would expand the potential market for ATH-1017 and diversify the company's pipeline. The Parkinson's disease market is projected to reach $8.2 billion by 2030. A successful outcome could position Athira as a player in this significant market. Timeline: Ongoing Phase 2 trials.
- Development of ATH-1019 for Peripheral Nervous System Indications: Athira's preclinical program, ATH-1019, targets peripheral nervous system disorders. Successful preclinical development and subsequent clinical trials could open up a new therapeutic area for the company. The market for peripheral neuropathy treatment is expected to grow, driven by the increasing prevalence of diabetes and other risk factors. Timeline: Preclinical stage.
- Development of ATH-1020 for Neuropsychiatric Conditions: Athira is also developing ATH-1020 for neuropsychiatric conditions. This program represents a longer-term growth opportunity, as it is currently in the preclinical stage. The market for neuropsychiatric drugs is substantial, but also highly competitive. Timeline: Preclinical stage.
- Potential for Strategic Partnerships: Given its limited resources, Athira may seek strategic partnerships with larger pharmaceutical companies to support the development and commercialization of its product candidates. Such partnerships could provide access to funding, expertise, and global distribution networks, accelerating the company's growth. Timeline: Ongoing.
What Opportunities Does ATHA Have?
- Successful completion of clinical trials and regulatory approval.
- Strategic partnerships with larger pharmaceutical companies.
- Expansion into new therapeutic areas.
- Growing market for neurodegenerative disease treatments.
What Threats Does ATHA Face?
- Clinical trial failures.
- Regulatory hurdles.
- Competition from larger pharmaceutical companies.
- Patent challenges.
What Are ATHA's Competitive Advantages?
- Proprietary small molecule therapeutics targeting neurodegenerative diseases.
- Patent protection for ATH-1017 and other product candidates.
- Clinical trial data demonstrating safety and efficacy.
- Expertise in HGF/MET pathway modulation.
What Does ATHA Do?
Athira Pharma, Inc., established in 2011 and headquartered in Bothell, Washington, is a biopharmaceutical company dedicated to developing innovative therapies for neurodegenerative diseases. Originally named M3 Biotechnology, Inc., the company rebranded as Athira Pharma in April 2019 to reflect its evolved focus. The company's core mission centers around restoring neuronal health and slowing neurodegeneration through the development of small molecule therapeutics. Their lead product candidate, ATH-1017, is a blood-brain barrier penetrating molecule designed to positively modulate the HGF/MET pathway. This pathway is crucial for neuronal survival and function. ATH-1017 is currently undergoing Phase 3 (LIFT-AD) and Phase 2 (ACT-AD) clinical trials for Alzheimer's disease, as well as Phase 2 trials for Parkinson's disease. Beyond ATH-1017, Athira is also advancing preclinical programs, including ATH-1019 for peripheral nervous system indications and ATH-1020 for neuropsychiatric conditions. Athira's strategy involves targeting the underlying mechanisms of neurodegeneration to provide disease-modifying treatments.
What Products and Services Does ATHA Offer?
- Develop small molecule therapeutics for neurodegenerative diseases.
- Focus on restoring neuronal health and slowing neurodegeneration.
- Advance ATH-1017, a HGF/MET positive modulator, through clinical trials.
- Target Alzheimer's disease and Parkinson's disease with ATH-1017.
- Develop preclinical programs for peripheral nervous system and neuropsychiatric conditions.
- Conduct Phase 3 clinical trials for ATH-1017 in Alzheimer's disease (LIFT-AD).
How Does ATHA Make Money?
- Develop and patent novel small molecule therapeutics.
- Conduct preclinical and clinical trials to demonstrate safety and efficacy.
- Seek regulatory approval from the FDA and other agencies.
- Potentially commercialize products directly or through partnerships.
What Industry Does ATHA Operate In?
Athira Pharma operates within the biotechnology industry, specifically targeting the neurodegenerative disease market. This market is characterized by high unmet needs, particularly in Alzheimer's and Parkinson's diseases. The competitive landscape includes major pharmaceutical companies and smaller biotech firms, all vying to develop effective treatments. The industry is driven by an aging global population and increasing prevalence of neurodegenerative disorders. Success in this field requires significant investment in research and development, navigating complex regulatory pathways, and demonstrating clinical efficacy. The Alzheimer's disease market is projected to reach billions of dollars in the coming years, creating a substantial opportunity for companies like Athira with promising therapeutic candidates.
Who Are ATHA's Key Customers?
- Patients suffering from Alzheimer's disease.
- Patients suffering from Parkinson's disease.
- Healthcare providers who treat these patients.
- Potential pharmaceutical partners.
Company Profile
Athira Pharma, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Bothell, US. The company is led by CEO Mark J. Litton. ATHA has traded publicly since 2020.
Athira Pharma, Inc. (ATHA) Valuation Context
Valued at $26.62M, ATHA is classified as a micro-cap stock. Relative to its peer group, ATHA's quantitative score of 44/100 is below the peer average of 75/100.
F-Score 2/9Financial Health
Athira Pharma, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -9.26 places it in the distress zone, a signal of elevated financial risk.
FY2026 estForward Outlook
Wall Street analysts project Athira Pharma, Inc. revenue of about $13.4M for fiscal 2026, with EPS near $-4.87.
ATHA Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Novel approach to treating neurodegenerative diseases by restoring neuronal health.
- Lead product candidate, ATH-1017, in Phase 3 clinical trials.
- Experienced management team with expertise in drug development.
- Proprietary small molecule platform.
Bear Case
- Limited financial resources.
- High dependence on the success of ATH-1017.
- Small number of employees (26).
- High beta of 2.80, indicating high volatility.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
ATHA Latest News
No recent news available for ATHA.
ATHA Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ATHA.
Price Targets
Consensus target: $4.00
ATHA MoonshotScore
What does this score mean?
The MoonshotScore rates ATHA's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Mark J. Litton
CEO
Mark J. Litton serves as the Chief Executive Officer of Athira Pharma, bringing extensive experience in the biopharmaceutical industry. His career spans various leadership roles in both large and emerging companies, with a focus on strategic planning, business development, and commercialization. Prior to Athira, Litton held key positions at Alder BioPharmaceuticals (acquired by Lundbeck), where he oversaw commercial strategy and operations. He also has experience at companies like Celltech and UCB. Litton holds an MBA from the University of Washington and a BS in Biology from Indiana University.
Track Record: Since joining Athira Pharma, Mark Litton has guided the company through critical clinical trial milestones for ATH-1017, including the initiation and ongoing progress of the LIFT-AD Phase 3 trial. He has also overseen the advancement of the company's preclinical programs and managed the company's financial resources. His leadership has been instrumental in securing funding and building a strong team to support Athira's growth.
ATHA Healthcare Stock FAQ
What does Athira Pharma, Inc. do?
Athira Pharma, Inc. is a biopharmaceutical company focused on developing small molecule therapeutics to address neurodegenerative diseases, such as Alzheimer's and Parkinson's. Their lead product candidate, ATH-1017, is designed to enhance neuronal health and slow neurodegeneration by modulating the HGF/MET pathway. Currently, ATH-1017 is undergoing Phase 3 clinical trials for Alzheimer's disease and Phase 2 trials for Parkinson's disease. The company also has preclinical programs targeting other neurological conditions, aiming to provide disease-modifying treatments for patients with limited options.
What do analysts say about ATHA stock?
Analyst coverage of Athira Pharma (ATHA) is limited, reflecting its status as a clinical-stage biotechnology company. Key valuation metrics are heavily influenced by the potential success of ATH-1017 in clinical trials. Positive data from the ongoing Phase 3 trial (LIFT-AD) could significantly increase analyst price targets. Conversely, negative or inconclusive results could lead to downgrades. Investors should carefully consider the inherent risks and uncertainties associated with clinical-stage biotech companies when evaluating ATHA stock.
What are the main risks for ATHA?
The primary risks for Athira Pharma stem from the inherent uncertainties of clinical drug development. Failure to demonstrate efficacy or safety in clinical trials would significantly impact the company's prospects. Regulatory hurdles, including potential delays or rejection by the FDA, also pose a substantial risk. Competition from larger pharmaceutical companies with greater resources is another factor to consider. Additionally, Athira's financial position and dependence on securing additional funding to support operations represent ongoing risks.
What are the key factors to evaluate for ATHA?
Athira Pharma, Inc. (ATHA) holds an AI score of 44/100 (low). Analysts target $4.00 (-41%). Not financial advice.
How frequently does ATHA data refresh on this page?
ATHA prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven ATHA's recent stock price performance?
Athira Pharma, Inc. (ATHA) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Novel approach to treating neurodegenerative diseases by restoring neuronal health. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ATHA overvalued or undervalued right now?
Valuing Athira Pharma, Inc. (ATHA) requires multiple metrics. Analysts target $4.00 (-41%) — downside risk seen. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying ATHA?
Before investing in Athira Pharma, Inc. (ATHA), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- Clinical trial outcomes are inherently uncertain.